Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Holding PCRX?
Track your performance easily
PCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.16 - $35.95
Previous Close$19.86
Volume702.91K
Average Volume (3M)759.16K
Market Cap
$917.00M
Enterprise Value$1.11B
Total Cash (Recent Filing)$453.81M
Total Debt (Recent Filing)$644.42M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 27, 2025EPS Estimate
$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding46,173,240
10 Day Avg. Volume1,036,111
30 Day Avg. Volume759,156
Standard Deviation0.11
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.22
Price to Sales (P/S)1.32
Price to Cash Flow (P/CF)4.30
P/FCF Ratio4.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit2.26
Enterprise Value/Ebitda-74.12
Forecast
1Y Price Target
$19.29Price Target Upside-2.92% Downside
Rating ConsensusHold
Number of Analyst Covering8
Pacira Pharmaceuticals News
PremiumCompany Announcements
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments
PremiumCompany Announcements
Pacira Pharmaceuticals Faces Q3 Loss Amid Revenue GrowthBulls Say, Bears Say
Bulls Say
Financial PerformancePacira generated its second highest quarterly cash flow ever, indicating strong financial health.
Patent ProtectionA new patent expiring in 2044 significantly strengthens Pacira's defenses against generic competition.
Product Growth PotentialExparel has significant growth potential in NOPAIN environment.
Bears Say
Financial Performance3Q24 results were unremarkable, which was expected given the focus on preparing for 2025.
Legal ChallengesLegal overhang will persist/limit multiple expansion.
Patent IssuesConcern about Exparel exclusivity following the patent invalidation which hit the stock.
---
Ownership Overview
1.55% Insiders
26.34% Mutual Funds
16.45% Other Institutional Investors
16.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $11.16 and its highest was $35.95 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.704 by $0.086.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Overvalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is $0.79.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,173,240 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.79 in its last earnings report, beating expectations of $0.704. Following the earnings report the stock price went up 0.17%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Pacira Pharmaceuticals’s shares valued at 1M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.29 (-2.92% Downside)
$19.29 (-2.92% Downside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 416.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.53%
12-Months-Change
Fundamentals
Return on Equity
-11.48%
Trailing 12-Months
Asset Growth
-0.83%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
PCRX Earnings Call
Q3 2024
0:00 / 0:00
---
PCRX Stock 12 Month Forecast
Average Price Target
$19.29
▼(-2.92% Downside)
Technical Analysis
Supernus Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
Dr Reddy's Laboratories
―
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
14/41 ratings generated profit
1 Year Average Return
-6.94%
reiterated a buy rating 18 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 34.15% of your transactions generating a profit, with an average return of -6.94% per trade.
---